NIH Resists “March In” On Norvir Patents Based On Pricing Concerns
This article was originally published in The Pink Sheet Daily
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.
You may also be interested in...
Astellas/Medivation prostate cancer drug is the latest focus of drug pricing criticism in the news but it doesn’t seem likely that NIH will grant open licenses on the drug’s patent under its “march-in” authority, as legislators and advocacy groups request.
Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.
GAO report concludes that although never employed, Bayh-Dole power "is particularly valuable as leverage in informal discussions."